project-idea
BRCA-Lung Immunotherapy Eligibility Explorer
BRCA1/2 mutations in lung adenocarcinoma predict better responses to immune checkpoint blockade despite worse overall prognosis — creating a paradox that clinicians need tools to navigate when making immunotherapy decisions for NSCLC patients.